<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hipertensión &#187; Terapia combinada</title>
	<atom:link href="https://temas.sld.cu/hipertension/tag/terapia-combinada/feed/" rel="self" type="application/rss+xml" />
	<link>https://temas.sld.cu/hipertension</link>
	<description>Sitio web dedicado a la hipertensión en Cuba</description>
	<lastBuildDate>Fri, 06 Jun 2025 14:42:55 +0000</lastBuildDate>
	<language>es-ES</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
	<item>
		<title>Estudio HOPE 3</title>
		<link>https://temas.sld.cu/hipertension/2016/04/21/hope-3/</link>
		<comments>https://temas.sld.cu/hipertension/2016/04/21/hope-3/#comments</comments>
		<pubDate>Thu, 21 Apr 2016 01:27:18 +0000</pubDate>
		<dc:creator><![CDATA[hipertension]]></dc:creator>
				<category><![CDATA[Investigaciones extranjeras]]></category>
		<category><![CDATA[Adultos mayores]]></category>
		<category><![CDATA[Afecciones cardiovasculares]]></category>
		<category><![CDATA[Prevención]]></category>
		<category><![CDATA[Terapéutica]]></category>
		<category><![CDATA[Terapia combinada]]></category>

		<guid isPermaLink="false">http://temas.sld.cu/hipertension/?p=5043</guid>
		<description><![CDATA[¿Es posible contrarrestar los eventos cardiovasculares antes de que la persona enferme? Los valores del colesterol y la presión arterial (PA) pueden reducirse de manera efectiva y segura con estatinas y medicamentos antihipertensivos, lo que a su vez reduciría en 20% &#8211; 30% la aparición de eventos cardiovasculares mayores (CV) por 5 años en individuos [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/hipertension/2016/04/21/hope-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial</title>
		<link>https://temas.sld.cu/hipertension/2012/07/09/losartanhydrochlorothiazide-combination-vs-high-dose-losartan-in-patients-with-morning-hypertension-a-prospective-randomized-open-labeled-parallel-group-multicenter-trial/</link>
		<comments>https://temas.sld.cu/hipertension/2012/07/09/losartanhydrochlorothiazide-combination-vs-high-dose-losartan-in-patients-with-morning-hypertension-a-prospective-randomized-open-labeled-parallel-group-multicenter-trial/#comments</comments>
		<pubDate>Mon, 09 Jul 2012 13:46:46 +0000</pubDate>
		<dc:creator><![CDATA[hipertension]]></dc:creator>
				<category><![CDATA[Propuestas del editor]]></category>
		<category><![CDATA[Hidroclorotiazida]]></category>
		<category><![CDATA[Losartan]]></category>
		<category><![CDATA[Terapia combinada]]></category>

		<guid isPermaLink="false">http://articulos.sld.cu/hta/?p=1616</guid>
		<description><![CDATA[Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial Por: Tamenobu Ueda, Hisashi Kai y Tsutomu Imaizumi1 on behalf of the MAPPY Study Investigators. Hypertension Research (2012) 35, 708–714. The treatment of morning hypertension has not been established. We compared the efficacy and safety of a losartan/hydrochlorothiazide (HCTZ) [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/hipertension/2012/07/09/losartanhydrochlorothiazide-combination-vs-high-dose-losartan-in-patients-with-morning-hypertension-a-prospective-randomized-open-labeled-parallel-group-multicenter-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.</title>
		<link>https://temas.sld.cu/hipertension/2012/04/24/combination-therapy-for-hypertension-in-the-elderly-a-sub-analysis-of-the-combination-therapy-of-hypertension-to-prevent-cardiovascular-events-cope-trial/</link>
		<comments>https://temas.sld.cu/hipertension/2012/04/24/combination-therapy-for-hypertension-in-the-elderly-a-sub-analysis-of-the-combination-therapy-of-hypertension-to-prevent-cardiovascular-events-cope-trial/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 18:12:05 +0000</pubDate>
		<dc:creator><![CDATA[hipertension]]></dc:creator>
				<category><![CDATA[Propuestas del editor]]></category>
		<category><![CDATA[Adultos mayores]]></category>
		<category><![CDATA[Prevención]]></category>
		<category><![CDATA[Sexo masculino]]></category>
		<category><![CDATA[Terapia combinada]]></category>

		<guid isPermaLink="false">http://articulos.sld.cu/hta/?p=1410</guid>
		<description><![CDATA[Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Por: Toshio Ogihara, Masunori Matsuzaki, Seiji Umemoto, Hiromi Rakugi, Hiroaki Matsuoka, Kazuyuki Shimada, Jitsuo Higaki, Sadayoshi Ito, Akira Kamiya, Hiromichi Suzuki, Yasuo Ohashi, Kazuaki Shimamoto y Takao Saruta for the Combination Therapy of Hypertension [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/hipertension/2012/04/24/combination-therapy-for-hypertension-in-the-elderly-a-sub-analysis-of-the-combination-therapy-of-hypertension-to-prevent-cardiovascular-events-cope-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
